• About us
• Contact

Advertisement

Organisation › Details

Biogen Inc. (Nasdaq: BIIB)

Through cutting-edge science and medicine, Biogen discovers, develops and delivers to patients worldwide innovative therapies for the treatment of neurodegenerative diseases, hematologic conditions and autoimmune disorders. Founded in 1978, Biogen is one of the world’s oldest independent biotechnology companies and patients worldwide benefit from its leading multiple sclerosis and innovative hemophilia therapies. *

 

	Start	2015-03-23 renamed
	Group	Biogen (Group)
	Predecessor	Biogen Idec Inc. (Nasdaq: BIIB)
	Industry	BIOTECH
	Region	Cambridge, MA
	Country	United States (USA)
	Street	225 Binney Street
	City	02142 Cambridge, MA
	Tel	+1-781-464-2000
		Address record changed: 2020-12-02
Basic data	Employees	n. a.
		* Document for »About Section«:
		Record changed: 2024-08-24

Advertisement

More documents for Biogen (Group)

• [1] Jeito Capital. (5/22/24). "Press Release: Jeito Capital Announces Acquisition of Portfolio Company HI-Bio by Biogen Inc. (Nasdaq: BIIB) for up to $1.8 Billion". Paris....
• [2] Biogen Inc.. (5/22/24). "Press Release: Biogen Bolsters Late-Stage Pipeline, Expands Immunology Portfolio with Agreement to Acquire Human Immunology Biosciences". Cambridge, MA & South San Francisco, CA....
• [3] Human Immunology Biosciences, Inc. (HI-Bio). (1/4/24). "Press Release: HI-Bio Announces $95 Million Series B Financing to Advance Targeted Therapies for Immune-Mediated Diseases". South San Francisco, CA....
• [4] Biogen Inc.. (7/28/23). "Press Release: Biogen to Acquire Reata Pharmaceuticals". Cambridge, MA & Plano, TX....
• [5] Anjarium Biosciences AG. (7/12/22). "Press Release: Anjarium Biosciences Appoints Experienced Industry Executives Samantha Vieira as Chief Operating Officer and Nate Massari as Chief Business Officer". Zurich....
• [6] MorphoSys AG. (6/14/22). "Press Release: MorphoSys and HIBio Enter Into Equity Participation and License Agreements for Felzartamab and MOR210". Planegg & South San Francisco, CA....
• [7] Envisagenics, Inc.. (5/13/21). "Press Release: Biogen and Envisagenics Announce Collaboration to Advance RNA Splicing Research". Cambridge, MA & New York, NY....
• [8] Cevec Pharmaceuticals GmbH. (1/8/21). "Press Release: Cevec Announces New License Agreement for Its AAV Manufacturing Technology Elevecta in Gene Therapy". Cologne....
• [9] ViGeneron GmbH. (1/5/21). "Press Release: ViGeneron Signs Global Collaboration Agreement for Ophthalmic Gene Therapy Development". Munich....
• [10] Merck KGaA. (12/11/20). "Press Release: Bavencio (avelumab) Receives Positive CHMP Opinion for First-line Maintenance Treatment of Locally Advanced or Metastatic Urothelial Carcinoma". Darmstadt....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2025. Made in Germany.